Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn's Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial.

Adv Ther · 2026 · PMC13222256 · PMID 41910935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Super-responders were also characterised by the highest pre-dose serum infliximab levels throughout maintenance treatment (from week 10) and showed a trend towards having lower baseline body weight and BMI, and higher baseline clinical and endoscopic disease activity, compared with other response trajectories.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.